Guided Therapeutics (GTHP) Notes Payables (2011 - 2025)

Guided Therapeutics has disclosed Notes Payables across 15 years of filings, most recently posting $105000.0 for Q4 2025.

• Notes Payables for Q4 2025 came in at $105000.0, down 24.46% year-over-year; the trailing twelve-month figure through Dec 2025 was $105000.0 (down 24.46% YoY), and the FY2025 annual result was $105000.0, down 24.46% from the prior year.
• Notes Payables came in at $105000.0 for Q4 2025 at Guided Therapeutics, down from $411000.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $421000.0 in Q2 2025 to a low of $11000.0 in Q1 2021.
• The 5-year median for Notes Payables is $59000.0 (2023), against an average of $109558.9.
• Across the five-year window, Notes Payables slumped 98.51% in 2021 and jumped 452.94% in 2023, its largest moves.
• Guided Therapeutics' Notes Payables stood at $48000.0 in 2021, then rose by 17.85% to $56569.0 in 2022, then increased by 4.3% to $59000.0 in 2023, then surged by 135.59% to $139000.0 in 2024, then slipped by 24.46% to $105000.0 in 2025.
• The last three Notes Payables figures came in at $105000.0 (Q4 2025), $411000.0 (Q3 2025), and $421000.0 (Q2 2025), per Business Quant data.